哈药集团股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 哈药集团股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开了第九届董事会第三十八次会议及第九届监事会第二十次会 议，审议通过了《2023 年 1-6 月计提资产减值准备的议案》，现将具 体情况公告如下： 证券代码:600664 证券简称:哈药股份 编号:临 2023-047 公司至少于每年年度终了，对固定资产逐项进行检查，如果发现 由于市价持续下跌，或技术陈旧、损坏、长期闲置等原因导致其可收 回金额低于其账面价值的，对其可收回金额低于其账面价值的差额计 提固定资产减值准备。按单项固定资产计提减值准备，并计入当期损 益。 2023 年 1-6 月固定资产减值准备母公司无计提，因资产处置或 报废原因减少 3.62 万元，期末余额为 10,030.41 万元；合并无计提， 因资产处置或报废原因减少 9.78 万元，期末余额为 13,493.20 万元。 一、计提资产减值准备的概述 为真实、公允地反映公司的财务状况和经 ...

公司本次计提资产减值准备遵照并符合《企业会计准则》、《公司 资产减值准备提取和核销规则》和公司相关会计政策的规定，本次计 提资产减值准备基于会计谨慎性原则，计提依据充分，并能真实地反 映公司资产价值及财务状况，有助于为投资者提供更可靠的会计信息。 因此，同意公司计提该项资产减值准备。 哈药集团股份有限公司独立董事： 潘广成、卢卫红、娄爱东、李兆华 二〇二三年八月二十四日 哈药集团股份有限公司独立董事 关于公司九届三十八次董事会相关事项的独立意见 根据《上市公司独立董事规则》、《上市公司治理准则》、《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规 和规范性文件及《公司章程》的有关规定，我们作为哈药集团股份有 限公司（以下简称"公司"）的独立董事，基于客观、独立的立场、 审慎负责的态度对公司九届三十八次董事会审议的《2023 年 1-6 月 计提资产减值准备的议案》发表如下独立意见： 1 ...

公司 2023 年 1-6 月合并财务报表中计提的资产减值准备情况如 下：坏账准备合并计提 2,241.41 万元，存货跌价准备合并计提 2,250.82 万元，本期合并计提 4,492.23 万元，转回 1,817.98 万元, 转销 2,168.71 万元，影响公司本期利润总额 505.54 万元。 具 体 内 容 详 见 公 司 同 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《哈药集团股份有限公司关于计提资产减 值准备的公告》。 一、2023 年半年度报告全文及摘要（同意 9 票，反对 0 票，弃 权 0 票） 具 体 内 容 详 见 公 司 同 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的 2023 年半年度报告全文及摘要。 二、2023 年 1-6 月计提资产减值准备的议案（同意 9 票，反对 0 票，弃权 0 票） 公司依据《企业会计准则》以及所在行业和公司资产的实际情况 计提资产减值准备，本次计提资产减值准备依据充分，真实地反映公 司财务状况和对公司经营成果的影响，公司董事会同意计提本次资产 减值准备。 证券代码:60 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-044 二、项目进展 本次被征收的标的房屋为公司非核心资产，已闲置多年， 协议的最终履行将有利于公司盘活资产，提高资产运营效率， 增加公司流动资金。根据《企业会计准则》等相关规定，公司 预期获得补偿款 123,264,303.91 元,已于 2022 年确认资产处 置收益，扣除相关税费后影响 2022 年度损益 90,790,944.04 元。本次收到的首期征收补偿款 31,051,438.58 元,对公司当 期损益无影响，具体会计处理及金额以年审会计师年度审计确 认后的结果为准。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性 承担法律责任。 一、交易概述 经哈药集团股份有限公司（以下简称"公司"）2022 年 12 月 6 日第九届董事会第三十二次会议审议，同意松北区人民政 府对本公司下属公司哈药集团三精制药有限公司所有的哈尔 滨市松北区前进乡金星村房屋进行征收，具体内容详见公司于 上海证券交易所网站（www.sse.com.cn）上披露的《哈药集团 股份有限公司九届三十二 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-036 哈药集团股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者 网上集体接待日活动暨 2022 年度业绩说明会的 公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 15 日(星期一)下午 14:00-16:30 会议召开地点："全景路演"网站（http://rs.p5w.net） 会议召开方式：网络远程方式 投资者可于 2023 年 5 月 10 日(星期三)至 5 月 12 日(星期五)16:00 前 将有关问题通过电子邮件的形式发送至公司邮箱：master@hayao.com。 公司将在信息披露允许的范围内对投资者普遍关注的问题进行回答。 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 下简称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与 深圳市全景网络有限公司联合举办的"2023 年黑龙江辖区上市公司 投资者集体接待日活动暨 2022 年度业绩说明会"，现将相关事项公 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-036 哈药集团股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者 网上集体接待日活动暨 2022 年度业绩说明会的 公告 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 下简称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与 深圳市全景网络有限公司联合举办的"2023 年黑龙江辖区上市公司 投资者集体接待日活动暨 2022 年度业绩说明会"，现将相关事项公 告如下： 一、说明会类型 本次活动将采用网络远程的方式举行，投资者可就公司 2022 年 度业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 15 日下午 14:00-16:30 会议召开时间：2023 年 5 月 15 日(星期一)下午 14:00-16:30 会议召开地点："全景路演"网站（http://rs.p5w.net） 会议召开方式：网络远程方式 投资者可于 2023 年 5 月 10 日(星期三)至 5 月 12 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3,931,549,972.98, representing a year-on-year increase of 17.93%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 122,293,236.02, up 21.75% compared to the same period last year[4] - Basic earnings per share for Q1 2023 were CNY 0.05, an increase of 25.00% from the previous year[4] - Total operating revenue for Q1 2023 reached ¥3,931,549,972.98, a 17.9% increase from ¥3,333,837,987.01 in Q1 2022[16] - Net profit for Q1 2023 was ¥139,987,574.96, representing a 27.4% increase compared to ¥109,934,338.19 in Q1 2022[17] - Total comprehensive income for Q1 2023 was ¥141,147,470.62, compared to ¥110,203,928.60 in Q1 2022, reflecting a growth of 28.1%[18] Cash Flow - The net cash flow from operating activities was CNY 182,625,091.63, reflecting a 17.91% increase year-on-year[4] - Cash inflow from operating activities in Q1 2023 was ¥4,022,411,651.90, up 22.7% from ¥3,277,424,882.21 in Q1 2022[20] - Net cash flow from operating activities for Q1 2023 was 182,625,091.63, an increase from 154,882,854.26 in Q1 2022, representing a growth of approximately 17.5%[21] - Net cash flow from financing activities was 62,865,637.35, a significant improvement from -5,098,076.67 in Q1 2022[22] - The company reported a net increase in cash and cash equivalents of 231,223,678.32, compared to 161,605,207.78 in the same period last year, representing a growth of approximately 43.0%[22] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 13,540,956,681.83, a 0.78% increase from the end of the previous year[4] - The company's total assets amounted to RMB 13,540,956,681.83, an increase from RMB 13,435,980,913.62 as of December 31, 2022, reflecting a growth of approximately 0.78%[15] - The company's total liabilities were RMB 8,447,947,901.95, down from RMB 8,484,927,244.36, representing a decrease of about 0.44%[14] - The company’s total liabilities to equity ratio improved to approximately 1.67 from 1.71, indicating a stronger equity position relative to liabilities[14] Expenses - The company's R&D expenses increased by 34.49% year-on-year, attributed to the expansion of R&D projects[6] - The company reported a 44.87% increase in sales expenses, driven by higher investment in health product business due to increased revenue[6] - Total operating costs for Q1 2023 were ¥3,749,463,341.18, up 18.0% from ¥3,175,613,101.54 in Q1 2022[16] - The company reported a decrease in financial expenses to ¥8,332,222.00 in Q1 2023 from ¥28,262,561.51 in Q1 2022[16] Shareholder Equity - The company's equity attributable to shareholders increased to RMB 4,455,333,420.22 from RMB 4,331,072,648.54, reflecting a growth of approximately 2.86%[14] - The company completed the repurchase and cancellation of 2,399,000 restricted stocks as part of its stock incentive plan, reducing total shares from 2,525,877,076 to 2,523,478,076[9]

Financial Performance - In 2022, the company's operating revenue reached CNY 13,808,761,327.75, an increase of 7.86% compared to CNY 12,802,015,553.25 in 2021[22]. - The net profit attributable to shareholders was CNY 464,359,718.95, representing a growth of 25.14% from CNY 371,083,746.30 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 230,751,956.99, up by 6.37% from CNY 216,930,409.23 in 2021[22]. - The net cash flow from operating activities was CNY 622,093,201.43, a significant recovery from a negative cash flow of CNY -162,437,381.47 in 2021[22]. - As of the end of 2022, the total assets amounted to CNY 13,435,980,913.62, reflecting a 4.62% increase from CNY 12,842,438,765.28 at the end of 2021[22]. - The net assets attributable to shareholders increased to CNY 4,331,072,648.54, a rise of 12.58% from CNY 3,847,233,622.82 in the previous year[22]. - The basic earnings per share increased to 0.19 yuan, up 26.67% from 0.15 yuan in 2021[23]. - The diluted earnings per share rose to 0.18 yuan, reflecting a 20.00% increase compared to the previous year[23]. - The gross profit margin for the main business was 24.56%, up 1.06 percentage points from the previous year[57]. - The overall gross profit margin for the company was 24.56%, which is close to the industry average[102]. Business Strategy and Operations - The company expanded its e-commerce business in the health product sector, leveraging existing resources to enhance market penetration[32]. - The company focused on optimizing product structure and expanding market share through new product introductions and enhanced customer services[33]. - The company emphasized the importance of strategic alliances with key customers to align with its development strategy[35]. - The establishment of a new subsidiary, Harbin Pharmaceutical Health Technology, focused on health products, aimed at rapid growth in online channels[35]. - The company has redefined its R&D strategy, focusing on digestive, respiratory, mineral, and chronic disease products, with an emphasis on rapidly developing health products as a key strategic initiative[36]. - The company operates seven core manufacturing bases to enhance its product and capacity advantages, optimizing the supply chain management to improve operational efficiency[37]. - The company has implemented cost control measures and lean management practices to improve its core competitiveness in product costs[37]. - The company is focusing on enhancing its R&D capabilities in biopharmaceuticals, with products including recombinant human erythropoietin injection and recombinant human granulocyte colony-stimulating factor injection[90]. - The company is committed to building a comprehensive product pipeline that spans prevention, treatment, recovery, and health maintenance[129]. Market and Industry Trends - In 2022, the pharmaceutical manufacturing industry reported revenues of CNY 2,911.14 billion, a year-on-year decrease of 1.6%, while operating costs increased by 7.8% to CNY 1,698.46 billion[38]. - The total profit for the pharmaceutical industry in 2022 was CNY 428.87 billion, reflecting a year-on-year decline of 31.8%[38]. - The new version of the medical insurance catalog includes 2,967 drugs, an increase of 107 from the previous version, indicating ongoing adjustments in the healthcare policy landscape[40]. - The health supplement industry in China is experiencing significant growth due to increased penetration and consumer stickiness, driven by policies such as the dual-track registration system for health foods[91]. - The pharmaceutical industry is facing challenges such as rising costs and intensified competition, with a projected average annual growth rate of over 8% in revenue and profit by 2025[126]. Risk Management and Compliance - There are no significant risks that could materially affect the company's operations during the reporting period[8]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has a standard unqualified audit report issued by Beijing Xinghua Accounting Firm[4]. - The company is committed to building a robust compliance management system to mitigate risks while promoting product marketing and terminal market maintenance[133]. - The company anticipates facing policy risks in 2023, including potential price reductions due to centralized procurement and changes in medical insurance payment methods[136]. Governance and Management - The company has established a governance structure that ensures effective decision-making and risk management, protecting shareholder rights[139]. - The board of directors has improved its structure, ensuring independent oversight and compliance with legal requirements[140]. - The company has revised 24 internal regulations, including the Articles of Association and various meeting rules, to comply with legal and regulatory requirements[146]. - The company has established a dedicated board secretary to oversee information disclosure and ensure equal access to information for all shareholders[142]. - The company has implemented measures to enhance the confidentiality of insider information, ensuring compliance with relevant regulations[142]. Research and Development - Research and development expenses increased by 18.49% to 115.81 million RMB, driven by accelerated new product development[55]. - The company is actively involved in multiple R&D projects across various therapeutic areas, including digestive, respiratory, and chronic diseases[103]. - The R&D investment capitalized ratio was 29.11%, indicating a significant portion of R&D expenses is being recognized as intangible assets[111]. - The company has successfully passed the consistency evaluation for four products, which is expected to enhance market share and competitiveness[106]. Sales and Marketing - The company has recovered core store operation rights on various e-commerce platforms and fully launched self-operated stores across all channels, enhancing its e-commerce business[44]. - Membership marketing efforts have led to a membership base of 2.19 million, with member sales accounting for 73.85% of total sales[46]. - The company is focusing on online sales while gradually expanding offline distribution based on existing pharmacy channel capabilities[116]. - The company plans to enhance its digital marketing efforts, with a budget increase of 25% to improve customer engagement and retention[151]. Future Outlook - The company plans to achieve a revenue of 14.814 billion yuan in 2023, representing a year-on-year growth of 7.28%[131]. - The net profit, excluding non-recurring gains and losses, is expected to reach 320 million yuan, with a year-on-year increase of 15.85%[131]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 2 billion RMB for potential deals[158]. - Future outlook indicates a projected revenue growth of 20% for the upcoming fiscal year, driven by new product launches and market expansion strategies[151].

证券代码：600664 证券简称：哈药股份 哈药集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 | √业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | □其他 | （请文字说明其他活动内容） | | 活动参与人 员 | 线上黑龙江辖区上市公司 绩说明会的投资者 | 2022 年投资者 ...

[Main Financial Data](index=1&type=section&id=Item%20I.%20Main%20Financial%20Data) [Core Financial Indicators](index=1&type=section&id=1.1%20Core%20Financial%20Indicators) The company's net profit attributable to shareholders significantly declined by 67.85% to **RMB 156 million** in the first three quarters of 2022, despite a slight revenue increase, primarily due to non-recurring items Key Financial Data for the First Three Quarters of 2022 | Indicator | Year-to-Date (RMB) | Y-o-Y Change (%) | Current Period (RMB) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 9.99 billion | 2.58% | 3.57 billion | 7.24% | | Net Profit Attributable to Shareholders of Listed Company | 156.42 million | -67.85% | 34.39 million | -76.19% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 123.72 million | -62.96% | 13.67 million | -89.81% | | Net Cash Flow from Operating Activities | 143.77 million | Not applicable | - | Not applicable | | Basic Earnings Per Share (RMB/share) | 0.06 | -68.42% | 0.01 | -83.33% | | Total Assets (Period-End) | 13.03 billion | 1.46% (vs. prior year-end) | - | - | Non-Recurring Gains and Losses for the First Three Quarters of 2022 | Item | Year-to-Date Amount (RMB) | Current Period Amount (RMB) | | :--- | :--- | :--- | | Gains/Losses from Disposal of Non-current Assets | 8.95 million | 7.46 million | | Government Grants | 32.13 million | 11.58 million | | Other Non-operating Income/Expenses | 1.55 million | 9.20 million | | **Total** | **32.70 million** | **20.72 million** | [Analysis of Key Financial Indicator Changes](index=2&type=section&id=1.2%20Analysis%20of%20Key%20Financial%20Indicator%20Changes) Significant changes in financial indicators include a **77.36% increase in prepayments** and a **35.57% rise in selling expenses**, while net profit attributable to the parent company sharply declined by 67.85% due to pandemic impacts and a high prior-year base Reasons for Changes in Key Accounting Data and Financial Indicators | Item | Change (%) | Primary Reason | | :--- | :--- | :--- | | Prepayments | 77.36 | Due to increased advance payments for goods in the current period | | Selling Expenses | 35.57 | Increased investment in selling expenses in the current period due to new business segments added in H2 2021 | | Non-operating Income | 329.64 | Due to subsidiary's cleanup of unpayable accounts | | Net Cash Flow from Investing Activities | -94.86 | Due to reduced disposal of idle assets and increased cash outflow for purchasing fixed and intangible assets compared to the prior period | | Net Profit Attributable to Shareholders of Listed Company | -67.85 | Main business sales decreased due to pandemic; non-operating gains/losses included asset disposal gains and employment stabilization subsidies in the prior period | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | -62.96 | Mainly due to restricted shipments during the pandemic, leading to decreased sales in the industrial sector | [Shareholder Information](index=3&type=section&id=Item%20II.%20Shareholder%20Information) [Shareholding Status of Shareholders](index=3&type=section&id=2.1%20Shareholding%20Status%20of%20Shareholders) As of Q3 2022, the company had **113,055 common shareholders**, with controlling shareholder Harbin Pharmaceutical Group Co., Ltd. holding **46.47%** of shares, of which approximately **79% are pledged** - As of the end of the reporting period, the company had a total of **113,055** common shareholders[13](index=13&type=chunk) Top Ten Shareholders' Shareholding Status | Shareholder Name | Shareholding Ratio (%) | Number of Shares Held | Share Status | | :--- | :--- | :--- | :--- | | Harbin Pharmaceutical Group Co., Ltd. | 46.47 | 1,173,237,023 | Pledged 926,857,248 shares | | China Securities Investor Protection Fund Co., Ltd. | 2.21 | 55,725,125 | None | | Xia Chongyang | 1.40 | 35,300,000 | None | | Zhejiang Provincial Financial Development Co., Ltd. | 0.95 | 23,883,418 | None | | Sun Kun | 0.91 | 23,000,000 | None | | Harbin Tianxiang Weiye Investment Co., Ltd. | 0.46 | 11,700,000 | Frozen 11,700,000 shares | [Quarterly Financial Statements](index=4&type=section&id=Item%20IV.%20Quarterly%20Financial%20Statements) [Consolidated Balance Sheet](index=4&type=section&id=4.1%20Consolidated%20Balance%20Sheet) As of September 30, 2022, total assets reached **RMB 13.03 billion** (up 1.46%), total liabilities were **RMB 8.39 billion**, and equity attributable to parent company owners increased by 4.55% to **RMB 4.02 billion** Key Items of Consolidated Balance Sheet (Unit: RMB) | Item | September 30, 2022 | December 31, 2021 | Change Rate | | :--- | :--- | :--- | :--- | | **Total Assets** | 13.03 billion | 12.84 billion | 1.46% | | Total Current Assets | 9.07 billion | 8.73 billion | 3.83% | | Total Non-current Assets | 3.96 billion | 4.11 billion | -3.57% | | **Total Liabilities** | 8.39 billion | 8.42 billion | -0.35% | | Total Current Liabilities | 7.85 billion | 7.85 billion | -0.10% | | **Total Equity Attributable to Parent Company Owners** | 4.02 billion | 3.85 billion | 4.55% | [Consolidated Income Statement](index=7&type=section&id=4.2%20Consolidated%20Income%20Statement) In the first three quarters of 2022, total operating revenue grew by 2.58% to **RMB 9.99 billion**, but a **35.57% increase in selling expenses** and significantly lower asset disposal gains led to a **67.85% decline in net profit** attributable to the parent company to **RMB 156 million** Key Items of Consolidated Income Statement (Unit: RMB) | Item | First Three Quarters of 2022 | First Three Quarters of 2021 | Y-o-Y Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 9.99 billion | 9.74 billion | 2.58% | | Total Operating Costs | 9.68 billion | 9.17 billion | 5.54% | | Of which: Selling Expenses | 1.20 billion | 881.81 million | 35.57% | | Asset Disposal Gains | 9.36 million | 139.05 million | -93.27% | | Operating Profit | 320.47 million | 700.67 million | -54.27% | | Total Profit | 322.02 million | 685.06 million | -53.00% | | Net Profit | 197.87 million | 529.22 million | -62.61% | | Net Profit Attributable to Parent Company Shareholders | 156.42 million | 486.51 million | -67.85% | [Consolidated Cash Flow Statement](index=9&type=section&id=4.3%20Consolidated%20Cash%20Flow%20Statement) In the first three quarters of 2022, operating cash flow improved from a **RMB 156 million net outflow** to a **RMB 144 million net inflow**, while investing cash flow significantly decreased by **94.86%**, and financing cash flow turned positive due to increased borrowings Key Items of Consolidated Cash Flow Statement (Unit: RMB) | Item | First Three Quarters of 2022 | First Three Quarters of 2021 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 143.77 million | -156.13 million | | Net Cash Flow from Investing Activities | 4.98 million | 96.97 million | | Net Cash Flow from Financing Activities | 144.69 million | -9.36 million | | Net Increase in Cash and Cash Equivalents | 298.04 million | -69.30 million | | Cash and Cash Equivalents at Period-End | 1.49 billion | 827.70 million | - The improvement in operating cash flow is attributed to the company's enhanced inventory control, integrated management of collections and payments, and optimized allocation of receipts and disbursements, improving cash flow management quality[12](index=12&type=chunk)